332
7.9 Miscellaneous
Nowadays, numerous types of neutral, amphiphilic, modified cyclodextrins are
incorporated in the formulation development of novel drug delivery systems that
can enable effective delivery of drugs across mucosal or dermal membranes. As per
the biopharmaceutical classification system of drugs, poor drug solubility or poor
mucosa permeability attributes of drugs limit their pharmaceutical applications.
These cyclodextrin-based polymeric nanoparticles represent a more reliable drug
delivery system when compared with control nanoparticles; they displayed homogeneous bioadhesive interactions with the gastrointestinal mucosa due to the presence of several hydroxyl groups in cyclodextrin nanoparticles, which would promote
hydrogen bonding with the gut, subsequently enhancing the bioadhesive potential
(Agüeros et al. 2011). Furthermore, Luppi et al. (2011) examined the potential of
different cyclodextrins in nasal drug delivery using albumin nanoparticles for the
treatment of the most common neurodegenerative disorder Alzheimer’s disease to
validate their effect on the drug release, mucoadhesiveness of nanoparticles, and
permeability of model drug tacrine. In another approach, β-cyclodextrin was conjugated with chitosan and further quaternized with glycidyltrimethylammonium chloride for mucoadhesive drug delivery system.
Transdermal delivery of drugs has always been a challenging task due to barrier
property of skin; due to unique properties of cyclodextrin-based nanoparticles, they
represent an alternative choice for effective transdermal delivery of drugs. Maestrelli
et al. (2006) synthesized chitosan nanoparticles in the presence of cyclodextrin as a
nanocarrier system for the triclosan (an antifungal agent) and furosemide (a
diuretic). This nanocarrier system showed immediate drug release, followed by a
delayed-release of drug. It confirms the inclusion of the drug inside the cyclodextrin
cavity and later encapsulation inside the chitosan polymer. Thus, representing an
ideal nanocarrier system for transdermal drug delivery. Similarly, Khalil et al.
Table 7.3 (continued)
Drug/
mechanism
Amphiphilic
cylodextrin
Indication
Outcomes
offered by
amphiphilic
cylodextrin
nanoparticles
Historical
landmarks
References
Iodinin
β-Cyclodextrin Antileukemic
activity
Significant
cytotoxicity &
improved water
solubility
First report on
iodinin
amphiphilic
β-cyclodextrin
nanoparticles
Prandina
et al.
(2018)
Paclitaxel
β-Cyclodextrin Anticancer Stronger
antitumoral
activity in the
3D
multicellular
tumor mode
First report on
the 3D
multicellular
tumor mode
Varan et al.
(2018)
A. Pandey
7.9 Miscellaneous
Nowadays, numerous types of neutral, amphiphilic, modified cyclodextrins are
incorporated in the formulation development of novel drug delivery systems that
can enable effective delivery of drugs across mucosal or dermal membranes. As per
the biopharmaceutical classification system of drugs, poor drug solubility or poor
mucosa permeability attributes of drugs limit their pharmaceutical applications.
These cyclodextrin-based polymeric nanoparticles represent a more reliable drug
delivery system when compared with control nanoparticles; they displayed homogeneous bioadhesive interactions with the gastrointestinal mucosa due to the presence of several hydroxyl groups in cyclodextrin nanoparticles, which would promote
hydrogen bonding with the gut, subsequently enhancing the bioadhesive potential
(Agüeros et al. 2011). Furthermore, Luppi et al. (2011) examined the potential of
different cyclodextrins in nasal drug delivery using albumin nanoparticles for the
treatment of the most common neurodegenerative disorder Alzheimer’s disease to
validate their effect on the drug release, mucoadhesiveness of nanoparticles, and
permeability of model drug tacrine. In another approach, β-cyclodextrin was conjugated with chitosan and further quaternized with glycidyltrimethylammonium chloride for mucoadhesive drug delivery system.
Transdermal delivery of drugs has always been a challenging task due to barrier
property of skin; due to unique properties of cyclodextrin-based nanoparticles, they
represent an alternative choice for effective transdermal delivery of drugs. Maestrelli
et al. (2006) synthesized chitosan nanoparticles in the presence of cyclodextrin as a
nanocarrier system for the triclosan (an antifungal agent) and furosemide (a
diuretic). This nanocarrier system showed immediate drug release, followed by a
delayed-release of drug. It confirms the inclusion of the drug inside the cyclodextrin
cavity and later encapsulation inside the chitosan polymer. Thus, representing an
ideal nanocarrier system for transdermal drug delivery. Similarly, Khalil et al.
Table 7.3 (continued)
Drug/
mechanism
Amphiphilic
cylodextrin
Indication
Outcomes
offered by
amphiphilic
cylodextrin
nanoparticles
Historical
landmarks
References
Iodinin
β-Cyclodextrin Antileukemic
activity
Significant
cytotoxicity &
improved water
solubility
First report on
iodinin
amphiphilic
β-cyclodextrin
nanoparticles
Prandina
et al.
(2018)
Paclitaxel
β-Cyclodextrin Anticancer Stronger
antitumoral
activity in the
3D
multicellular
tumor mode
First report on
the 3D
multicellular
tumor mode
Varan et al.
(2018)
A. Pandey